{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:06:30Z","timestamp":1774566390933,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"DOI":"10.7759\/cureus.102669","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:56:01Z","timestamp":1769828161000},"source":"Crossref","is-referenced-by-count":1,"title":["Exceptional and Durable Complete Response to Ado-Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Yuko","family":"Tashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurie","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon DJ","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987, 235:177-82. 10.1126\/science.3798106","journal-title":"Science"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-positive breast cancer: current status and future perspectives","volume":"9","author":"Arteaga CL","year":"2011","unstructured":"Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011, 9:16-32. 10.1038\/nrclinonc.2011.177","journal-title":"Nat Rev Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop IE","year":"2017","unstructured":"Krop IE, Kim SB, Martin AG, et al.. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017, 18:743-54. 10.1016\/S1470-2045(17)30313-3","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L, et al.. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012, 367:1783-91. 10.1056\/NEJMoa1209124","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al.. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45:228-47. 10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115321","article-title":"Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes","volume":"219","author":"Griguolo G","year":"2025","unstructured":"Griguolo G, Bottosso M, Crema A, et al.. Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes. Eur J Cancer. 2025, 219:115321. 10.1016\/j.ejca.2025.115321","journal-title":"Eur J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: mechanisms of action and drug resistance","volume":"16","author":"Barok M","year":"2014","unstructured":"Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014, 16:209. 10.1186\/bcr3621","journal-title":"Breast Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1480287","article-title":"Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients","volume":"19","author":"Omarini C","year":"2018","unstructured":"Omarini C, Bettelli S, Caprera C, et al.. Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. Cancer Biol Ther. 2018, 19:879-86. 10.1080\/15384047.2018.1480287","journal-title":"Cancer Biol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00581","article-title":"Exceptional and durable responses to TDM-1 after trastuzumab failure for breast cancer skin metastases: potential implications of an immunological sanctuary","volume":"8","author":"Giarratano T","year":"2018","unstructured":"Giarratano T, Miglietta F, Giorgi CA, et al.. Exceptional and durable responses to TDM-1 after trastuzumab failure for breast cancer skin metastases: potential implications of an immunological sanctuary. Front Oncol. 2018, 8:581. 10.3389\/fonc.2018.00581","journal-title":"Front Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6036","article-title":"Long-time response with ado-trastuzumab emtansine in a recurrent metastatic breast cancer","volume":"11","author":"Manthri S","year":"2019","unstructured":"Manthri S, Singal S, Youssef B, Chakraborty K. Long-time response with ado-trastuzumab emtansine in a recurrent metastatic breast cancer. Cureus. 2019, 11:e6036. 10.7759\/cureus.6036","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1473","article-title":"Excellent response with ado-trastuzumab emtansine in a patient with relapsed metastatic breast cancer presenting with pulmonary lymphangitic carcinomatosis","volume":"9","author":"Yu Z","year":"2017","unstructured":"Yu Z, Sankar S, Huben M. Excellent response with ado-trastuzumab emtansine in a patient with relapsed metastatic breast cancer presenting with pulmonary lymphangitic carcinomatosis. Cureus. 2017, 9:e1473. 10.7759\/cureus.1473","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/455176-exceptional-and-durable-complete-response-to-ado-trastuzumab-emtansine-in-her2-positive-metastatic-breast-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:56:02Z","timestamp":1769828162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/455176-exceptional-and-durable-complete-response-to-ado-trastuzumab-emtansine-in-her2-positive-metastatic-breast-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.102669","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}